摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one | 328543-05-1

中文名称
——
中文别名
——
英文名称
1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one
英文别名
2-[4-(Diethoxymethyl)phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one
1-(4-Diethoxymethyl-phenyl)-8,9-dihydro-7H-2,7,9a-triaza-benzo[cd]azulen-6-one化学式
CAS
328543-05-1
化学式
C21H23N3O3
mdl
——
分子量
365.432
InChiKey
UALKJTNNHFZRMO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    65.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Tricyclic inhibitors of poly(ADP-ribose) polymerases
    申请人:Agouron Pharmaceuticals, Inc.
    公开号:US06548494B1
    公开(公告)日:2003-04-15
    Compounds of the formula shown below are poly(ADP-ribosyl)transferase inhibitors: Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.
    以下化学式显示的化合物是聚(ADP-核糖基)转移酶抑制剂:这些化合物在治疗癌症和改善中风、头部创伤和神经退行性疾病的疗效方面非常有用。
  • Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye
    申请人:Zhang Jinzhong
    公开号:US20080305994A1
    公开(公告)日:2008-12-11
    A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression.
  • US6548494B1
    申请人:——
    公开号:US6548494B1
    公开(公告)日:2003-04-15
  • [EN] PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉ PERMETTANT DE TRAITER, RÉDUIRE, AMÉLIORER, ATTÉNUER, OU PRÉVENIR LA SÉCHERESSE OCULAIRE
    申请人:BAUSCH & LOMB
    公开号:WO2008154129A1
    公开(公告)日:2008-12-18
    [EN] A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an ophthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase ("PARP"). The composition can also include a modulator of pro-inflammatory gene expression.
    [FR] La présente invention concerne une composition permettant de traiter, réduire, améliorer, atténuer, ou prévenir un état de sécheresse oculaire ou un trouble ophtalmologique d'origine inflammatoire qui comprend un inhibiteur de l'activité de poly(ADP-ribose)-polymérase ('PARP'). La composition peut également inclure un modulateur de l'expression de gène pro-inflammatoire.
  • Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors
    作者:Donald J. Skalitzky、Joseph T. Marakovits、Karen A. Maegley、Anne Ekker、Xiao-Hong Yu、Zdenek Hostomsky、Stephen E. Webber、Brian W. Eastman、Robert Almassy、Jianke Li、Nicola J. Curtin、David R. Newell、A. Hilary Calvert、Roger J. Griffin、Bernard T. Golding
    DOI:10.1021/jm0255769
    日期:2003.1.1
    Novel tricyclic benzimidazole carboxamide poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been synthesized. Several compounds were found to be powerful chemopotentiators of temozolomide and topotecan in both A549 and LoVo cell lines. In vitro inhibition of PARP-1 was confirmed by direct measurement of NAD(+) depletion and ADPribose polymer formation caused by chemically induced DNA damage.
查看更多